Shares of Innospec Inc. (NASDAQ:IOSP) have been assigned an average recommendation of “Hold” from the six analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $76.00.

IOSP has been the subject of several recent analyst reports. Monness Crespi & Hardt upgraded shares of Innospec from a “neutral” rating to a “buy” rating and set a $65.00 target price for the company in a research note on Tuesday, August 22nd. Zacks Investment Research upgraded shares of Innospec from a “hold” rating to a “buy” rating and set a $76.00 target price for the company in a research note on Friday, November 10th. KeyCorp restated an “overweight” rating on shares of Innospec in a research note on Thursday, November 9th. ValuEngine upgraded shares of Innospec from a “hold” rating to a “buy” rating in a research note on Thursday, November 9th. Finally, Johnson Rice upgraded shares of Innospec from a “hold” rating to an “accumulate” rating in a research note on Tuesday, November 14th.

In related news, VP Brian Watt sold 440 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $70.17, for a total value of $30,874.80. Following the completion of the sale, the vice president now owns 30,730 shares in the company, valued at $2,156,324.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Ian Cleminson sold 5,000 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $71.67, for a total transaction of $358,350.00. Following the completion of the sale, the chief financial officer now owns 22,997 shares of the company’s stock, valued at approximately $1,648,194.99. The disclosure for this sale can be found here. Insiders sold a total of 24,366 shares of company stock valued at $1,743,891 in the last 90 days. Company insiders own 2.02% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in IOSP. Aperio Group LLC lifted its stake in shares of Innospec by 12.6% in the second quarter. Aperio Group LLC now owns 7,279 shares of the specialty chemicals company’s stock valued at $477,000 after purchasing an additional 814 shares during the period. Strs Ohio lifted its stake in shares of Innospec by 6.3% in the second quarter. Strs Ohio now owns 13,600 shares of the specialty chemicals company’s stock valued at $891,000 after purchasing an additional 800 shares during the period. Great West Life Assurance Co. Can lifted its stake in shares of Innospec by 3.0% in the second quarter. Great West Life Assurance Co. Can now owns 35,015 shares of the specialty chemicals company’s stock valued at $2,293,000 after purchasing an additional 1,020 shares during the period. Texas Permanent School Fund lifted its stake in shares of Innospec by 1.1% in the second quarter. Texas Permanent School Fund now owns 17,618 shares of the specialty chemicals company’s stock valued at $1,155,000 after purchasing an additional 190 shares during the period. Finally, Sei Investments Co. lifted its stake in shares of Innospec by 100.1% in the second quarter. Sei Investments Co. now owns 36,827 shares of the specialty chemicals company’s stock valued at $2,414,000 after purchasing an additional 18,420 shares during the period. Hedge funds and other institutional investors own 91.20% of the company’s stock.

Shares of Innospec (IOSP) opened at $68.90 on Friday. The firm has a market cap of $1,692.04, a price-to-earnings ratio of 16.49 and a beta of 1.20. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.35 and a current ratio of 2.24. Innospec has a 52 week low of $54.10 and a 52 week high of $74.75.

Innospec (NASDAQ:IOSP) last released its earnings results on Tuesday, November 7th. The specialty chemicals company reported $1.00 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.15. Innospec had a net margin of 7.45% and a return on equity of 15.05%. The company had revenue of $332.40 million during the quarter, compared to analysts’ expectations of $309.40 million. During the same quarter last year, the business earned $0.78 EPS. The business’s revenue was up 61.8% on a year-over-year basis. analysts forecast that Innospec will post 4.3 earnings per share for the current year.

The company also recently announced a semiannual dividend, which was paid on Monday, November 27th. Stockholders of record on Thursday, November 16th were paid a $0.39 dividend. This represents a dividend yield of 1.12%. The ex-dividend date was Wednesday, November 15th. This is a boost from Innospec’s previous semiannual dividend of $0.38. Innospec’s dividend payout ratio (DPR) is 21.61%.

WARNING: “Innospec Inc. (IOSP) Given Consensus Recommendation of “Hold” by Analysts” was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/12/09/innospec-inc-iosp-given-consensus-recommendation-of-hold-by-analysts.html.

Innospec Company Profile

Innospec Inc is a specialty chemicals company engaged in developing, manufacturing, blending, marketing and supplying of specialty chemicals for use as fuel additives and ingredients for personal care, home care, agrochemical, mining and other applications and oilfield chemicals. The Company operates through four business segments: Fuel Specialties, Performance Chemicals, Oilfield Services and Octane Additives.

Receive News & Ratings for Innospec Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec Inc. and related companies with MarketBeat.com's FREE daily email newsletter.